Notice of approval of a venture originating from the National Cancer Center

Tokyo, Sep. 9, 2015


 We are pleased to announce that the National Cancer Center (President: Horita Tomomitsu; Location: Chuo-ku, Tokyo; hereinafter referred to as "NCC") has recognized Noile-Immune Biotech Inc., aiming for the development of a Japan-developed, breakthrough cancer immunotherapy medicine specialized in cancer immunotherapy as a venture company originating from the National Cancer Center.

 The NCC and Noile-Immune Biotech Inc. will contribute to the personal exchanges with researchers and physicians involved in R&D of cancer treatment medicine, and the growth of basic research and the search for seeds in the field of cancer treatment based on the collaboration with the Immunotherapy Development Department at the Exploratory Oncology Research & Clinical Trial Center (Yoshimura Kiyoshi department head, Nakatsura Tetsuya, department head). We will apply obtained results to clinical R&D to move forward with our aim of providing a new treatment for cancer sufferers as soon as possible.